ACT Genomics Global

ACT Genomics Global ACT Genomics is an internationally recognized award-winning cancer solution provider.

We are glad to share ACTMonitor® Breast is now expanded to 10-gene panel with the addition of AKT1 and PTEN biomarkers. ...
26/02/2026

We are glad to share ACTMonitor® Breast is now expanded to 10-gene panel with the addition of AKT1 and PTEN biomarkers. This enhancementis designed to broaden molecular insights available to clinicians andlaboratories supporting breast cancer monitoring and care.

Read the full article: https://smpl.is/aho3z

It's . Join us in exploring the latest landscape of precision medicine in biliary tract cancer, from molecular prof...
23/02/2026

It's . Join us in exploring the latest landscape of precision medicine in biliary tract cancer, from molecular profiling and RNA fusion testing to biomarker-driven treatment strategies. Full artcle: https://smpl.is/ahkts

15/02/2026

Galloping into the Year of the Horse with strength and momentum.🐎
ACT Genomics wishes you a healthy and successful Lunar New Year!

ACT Genomics at the 7th RMC Joint Conference: Pioneering Precision Medicine. It's our honor to share thoughts with onsit...
06/02/2026

ACT Genomics at the 7th RMC Joint Conference: Pioneering Precision Medicine. It's our honor to share thoughts with onsite physicians and discuss our latest publication.

23/12/2025

From every data point to every discovery, it’s people who give science its purpose. As the year comes to a close, we wish you and your family a season filled with hope, health, and new breakthroughs. 💙

2025 in action! Find ACT Genomics and DELBio at booth N429 in TaiNEX.
06/12/2025

2025 in action! Find ACT Genomics and DELBio at booth N429 in TaiNEX.

Meet us at the 2025 in Singapore! Glad to exchange thoughts and share the latest findings of with physicians.
06/12/2025

Meet us at the 2025 in Singapore! Glad to exchange thoughts and share the latest findings of with physicians.

The therapeutic landscape of -positive breast cancer continues to evolve—from positive to low and now ultra-low express...
11/11/2025

The therapeutic landscape of -positive breast cancer continues to evolve—from positive to low and now ultra-low expression categories.

Trastuzumab deruxtecan has redefined HER2-targeted therapy, extending clinical benefit to broader patient populations. This evolution, however, underscores the need for greater precision and consistency in HER2 assessment. Mass spectrometry-based clinical proteomics provides an advanced, quantitative, and reproducible solution that complements conventional IHC, enabling more accurate patient stratification and guiding the next generation of precision oncology.

Understand more, full article: https://smpl.is/aee74

Learn how Negative Hyperselection plays an important role in the recent advances in the treatment of metastatic colorect...
04/09/2025

Learn how Negative Hyperselection plays an important role in the recent advances in the treatment of metastatic colorectal cancer (mCRC) underscores the growing importance of personalized therapy.

Read the full article: https://smpl.is/abqgw

29/08/2025

ACT Genomics celebrates our anniversary today! 🎉
We are filled with gratitude — to our dedicated team and to all our partners who have joined forces with us in advancing precision medicine and making it more accessible to patients worldwide.

We were honored to participate in the Bangkok 2025 last weekend. The team exchanged valuable insights with physicians ...
25/08/2025

We were honored to participate in the Bangkok 2025 last weekend. The team exchanged valuable insights with physicians onsite. Making precision medicine accessible to Thailand jointly.

We are honored to have Professor Mok for an enlightening sharing of valuable insights and learnings from alongside our...
12/08/2025

We are honored to have Professor Mok for an enlightening sharing of valuable insights and learnings from alongside our CEO, Dr. Hua Chien Chen.

This special event, held in Hong Kong, brought together physicians and industry experts to discuss the latest advancements and innovations in oncology. It was a great opportunity to connect, learn, and discuss how these developments can be integrated into practice to enhance patient care.

Address

Singapore

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00

Telephone

+6568162530

Website

Alerts

Be the first to know and let us send you an email when ACT Genomics Global posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category